5Cervantes G,Torrecillas L,Eraro AA,et al.Capecitabine (Xeloda) as treatment after failure to taxanes for metastatic breast cancer.Proc Am Soc Clin Oncol,2000,19(5):121-129. 被引量：1
6Lum JL,Jones SE,Buzdar AU,et al.Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol,1999,17 (8):4851-4859. 被引量：1
7O'Reilly SM,Moiseyenko V,Talbot DC,et al.A randomized phase Ⅱ study of Xeloda(capecitabine)vs paclitaxel in breast cancer patients failing previous anthracycline therapy.Proc Am Soc Clin Oncol,1998,17(2):163-171. 被引量：1
8Ishikawa T,Utoh M,Sawada N,et al.Tumor seletive delivery offluorouracil by capecitabine,a new oral fluoropyrimidine carbamate,in human cancer xenografts.Biochem Pharmacol,1998,55(6):1091-1097. 被引量：1
9Ishikawa T,Sekiguchi F,Fukase Y,et al.Positive correlation between the efficacy of capecitabine and doxifluridine and the ration of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.Cancer Res,1998,58(6):685-690. 被引量：1
10Miwa M,Ura M,Nishida M,et al.Design of a novel oral fluoropyrimidine carbamate,capecitabine,which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancertissue.Eur J Cancer,1998,34(4):1274-1281. 被引量：1
1Conesa-Zamora P.Immune responses against virus and tumor in cervical carcinogenesis:treatment strategies for avoiding the HPV-induced immune escape[J].Gynecol Oncol,2013,131(2):480-488. 被引量：1
2Battaglia A,Buzzonetti A,Martinelli E,et al.Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer[J].Int J Radiat Oncol Biol Phys,2010,76(5):1546-1553. 被引量：1
3Fujiwara M,Isohashi F,Mabuchi S,et al.Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors[J].J Radiat Res,2014,56(2):305-314. 被引量：1
4Wang X,Wang T,Xu M,et al.B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas[J].Hum Immunol,2014,75(12):1203-1209. 被引量：1
5Li C,Ma C,Zhang W,et al.The immune function differences and high-risk human papillomavirus infection in the progress of cervical cancer[J].Eur J Gynaecol Oncol,2014,35(5):557-561. 被引量：1
6Bedoya AM,Tate DJ,Baena A,et al.Immunosuppression in cervical cancer with special reference to arginase activity[J].Gynecol Oncol,2014,135(1):74-80. 被引量：1
7Long J,Luo GP,Xiao ZW,et al.Cancer statistics:currentdiagnosis and treatment of pancreatic cancer in Shanghai,China[J].Cancer Lett,2014,346(2):273-277. 被引量：1
8Clark CE,Beatty GL,Vonderheide RH.Immunosurveillanceof pancreatic adenocarcinoma:insights from geneticallyengineered mouse models of cancer [J].Cancer Lett ,2009 ,279(1):1-7. 被引量：1
9Clark CE,Hingorani SR,Mick R,et al.Dynamics of theimmune reaction to pancreatic cancer from inception toinvasion[J].Cancer Res,2007,67(19):9518-9527. 被引量：1
10Mellman I,Coukos G,Dranoff G.Cancer immunotherapycomes of age[J].Nature,2011,480(7378):480-489. 被引量：1
